Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801098 | 1.00 | HPGDS (0.49) | HPGDSLMNAALDH1A1HTTMAPT | |
| SCHEMBL24975159 | 0.88 | HPGDS (0.49) | HPGDSLMNAALDH1A1HTTMAPT | |
| SCHEMBL29801077 | 0.88 | HPGDS (0.49) | HPGDSLMNAALDH1A1HTTMAPT | |
| SCHEMBL29801436 | 0.88 | TRPV1 (0.53) | HPGDSLMNAALDH1A1HTTMAPT | |
| SCHEMBL24975115 | 0.88 | TRPV1 (0.53) | HPGDSLMNAALDH1A1HTTMAPT | |
| SCHEMBL24975148 | 0.88 | ALDH1A1 (0.44) | HPGDSLMNAALDH1A1HTTMAPT | |
| SCHEMBL29801199 | 0.88 | ALDH1A1 (0.44) | HPGDSLMNAALDH1A1HTTMAPT | |
| SCHEMBL24975150 | 0.87 | EIF4E (0.44) | HPGDSLMNAALDH1A1HTTMAPT | |
| SCHEMBL29801005 | 0.87 | EIF4E (0.44) | HPGDSLMNAALDH1A1HTTMAPT | |
| SCHEMBL24975281 | 0.86 | HPGDS (0.49) | HPGDSLMNAALDH1A1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| CN-114929672-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, KIT, GLI1 | HPGDS 95/4885LMNA 2667/4885ALDH1A1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.